Now part of the BioNTech Group
CureVac (curevac.com) earns a Brand Analyzer score of 79 out of 100, placing it in the Brand-Ready tier among Healthcare brands. Among 2859 Healthcare brands analyzed, CureVac ranks in the 85th percentile (category average 70, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 100/100, Digital Presence 100/100, Visual Identity 60/100, Messaging Clarity 100/100, Trust Foundation 90/100, AI Discoverability 28/100, Brand Authority 58/100.
CureVac is a German biopharmaceutical company founded in 2000 and headquartered in Tübingen, focused on developing mRNA-based immunotherapies for cancer and other serious diseases. Now part of the BioNTech Group, CureVac contributes its mRNA technology expertise to accelerate the development of next-generation treatments. Its work targets patients, healthcare providers, biopharmaceutical partners, and researchers within the immunotherapy field, combining decades of mRNA research with BioNTech's broader immunotherapy platform.
| Brand Name | CureVac |
|---|---|
| Domain | curevac.com |
| Industry | Healthcare |
| Founded | 2000 |
| Headquarters | Tübingen |
| Parent Company / Owner | Dietmar Hopp |
| Main Competitors | Moderna (94/100), BioNTech (83/100), Sanofi (82/100), Arcturus Therapeutics, Translate Bio |
Moz Domain Authority 60/100 vs category average 32 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #353,321 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
CureVac has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "To pioneer novel immunotherapies that address cancer and other serious diseases through mRNA-based technology." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram, GitHub; no detected presence on Facebook, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
CureVac scores 57/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
CureVac has a limited AI-visibility profile at 57/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (70/100) and its weakest is trust (37/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #353,321 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify CureVac from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is CureVac?", Claude could identify the brand as of August 2026. CureVac is a German biopharmaceutical company based in Tübingen that pioneers mRNA-based technology for vaccines and therapeutics, including cancer treatments and infectious disease vaccines. Best known for Being an early pioneer of mRNA vaccine technology, particularly known for its COVID-19 vaccine candidate that ultimately underperformed in trials compared to Pf.
When asked "Best brands similar to CureVac?", Claude would recommend CureVac as of August 2026. It's a notable name in the mRNA therapeutics space alongside Moderna and BioNTech, though its clinical track record has been less successful than those peers.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
CureVac's main competitors include Moderna (94/100), BioNTech (83/100), Sanofi (82/100), Arcturus Therapeutics, Translate Bio. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
CureVac and Moderna are competitors in Healthcare. Brand Analyzer scores CureVac at 79/100 and Moderna at 94/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to CureVac include Moderna (94/100), BioNTech (83/100), Sanofi (82/100), Arcturus Therapeutics, Translate Bio. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
CureVac has moderate AI-search visibility, scoring 57/100 on Brand Analyzer's AI visibility composite (visibility 70, trust 37, recommendation 59). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: CureVac official site
CureVac was founded in 2000. CureVac operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
CureVac is headquartered in Tübingen. CureVac operates in the Healthcare category.
Sources: Wikidata
CureVac scores 59/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: CureVac official site
CureVac is a German biopharmaceutical company founded in 2000 and headquartered in Tübingen, specializing in mRNA-based technology for immunotherapies. It is now part of the BioNTech Group, contributing its mRNA expertise to the development of treatments for cancer and other serious diseases.
Sources: CureVac official site
CureVac develops mRNA-based immunotherapies aimed at treating cancer and other serious diseases. As part of the BioNTech Group, it combines its mRNA technology expertise with BioNTech's global immunotherapy platform to accelerate the development of next-generation treatments.
Sources: CureVac official site
CureVac can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: CureVac official site
CureVac focuses on developing mRNA-based immunotherapies targeting cancer and other serious diseases. Its work involves applying mRNA technology within the broader immunotherapy platform of the BioNTech Group to create next-generation therapeutic treatments.
Sources: CureVac official site
CureVac is owned by or part of Dietmar Hopp. CureVac operates in the Healthcare category.
Sources: Wikidata
CureVac is known for its pioneering work in mRNA technology applied to immunotherapy, particularly for cancer and other serious diseases. It is recognized as one of the early developers of mRNA-based therapeutic platforms and is now integrated into the BioNTech Group.
Sources: CureVac official site
CureVac's work is intended for patients suffering from cancer and other serious diseases, as well as healthcare providers, biopharmaceutical partners, and researchers in the immunotherapy field who rely on its mRNA technology and research contributions.
Sources: CureVac official site
Ranked closest to CureVac: CoRover (79/100), Colgate (79/100), Curogram (79/100), DaVita Kidney Care (79/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), Zimmer Biomet (81/100).
Category leader: Elsevier (96/100).